nebivolol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
beta-adrenoreceptor antagonists	1887	118457-14-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nebivolol nebivolol hydrochloride vasoxen bystolic nebivolol HCl	A cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine/ NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients. Molecular weight: 405.44 Formula: C22H25F2NO4 CLOGP: 3.50 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 70.95 ALOGS: -4 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nebivolol
nebivolol hydrochloride
vasoxen
bystolic
nebivolol HCl

A cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine/ NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients.

Molecular weight: 405.44
Formula: C22H25F2NO4
CLOGP: 3.50
LIPINSKI: 0
HAC: 5
HDO: 3
TPSA: 70.95
ALOGS: -4
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
5	mg	O

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.35 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	11 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	14 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 17, 2007	FDA	FOREST LABS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	195.98	11.09	433	29126	253435	53066072
Bradycardia	189.89	11.09	215	29344	70841	53248666
Hyponatraemia	145.84	11.09	235	29324	108372	53211135
Hypertensive crisis	118.92	11.09	83	29476	14423	53305084
Hypotension	95.11	11.09	333	29226	253743	53065764
Drug interaction	95.00	11.09	302	29257	219027	53100480
Rheumatoid arthritis	91.84	11.09	30	29529	314501	53005006
Anaemia	68.51	11.09	319	29240	276399	53043108
Joint swelling	57.67	11.09	29	29530	234609	53084898
Lip oedema	56.00	11.09	31	29528	3576	53315931
Acute motor-sensory axonal neuropathy	54.58	11.09	16	29543	339	53319168
Pain	52.60	11.09	160	29399	588238	52731269
Systemic lupus erythematosus	51.40	11.09	5	29554	125409	53194098
Traumatic coma	50.86	11.09	11	29548	61	53319446
Syncope	50.02	11.09	156	29403	111837	53207670
Fall	49.63	11.09	354	29205	358086	52961421
Treatment failure	47.98	11.09	7	29552	128396	53191111
Rhabdomyolysis	46.97	11.09	86	29473	43837	53275670
Synovitis	45.02	11.09	4	29555	107889	53211618
Hepatocellular injury	44.49	11.09	68	29491	29918	53289589
Hyperkalaemia	43.30	11.09	94	29465	54162	53265345
Drug ineffective	41.72	11.09	274	29285	816971	52502536
Ischaemic stroke	40.62	11.09	50	29509	17943	53301564
Maternal exposure during pregnancy	40.11	11.09	18	29541	155621	53163886
Cardiac failure	39.64	11.09	121	29438	85723	53233784
General physical health deterioration	38.95	11.09	173	29386	146769	53172738
Arthropathy	37.02	11.09	16	29543	141437	53178070
Product prescribing error	36.69	11.09	54	29505	22977	53296530
Glossodynia	36.26	11.09	6	29553	100285	53219222
Angina pectoris	35.57	11.09	60	29499	28665	53290842
Hypokalaemia	35.55	11.09	126	29433	96391	53223116
Atrial fibrillation	35.49	11.09	139	29420	111513	53207994
Melaena	34.96	11.09	60	29499	29069	53290438
Dyspnoea	33.48	11.09	482	29077	585750	52733757
Therapeutic product effect decreased	33.22	11.09	14	29545	125641	53193866
Cerebellar ataxia	32.88	11.09	14	29545	907	53318600
Vertigo	31.66	11.09	85	29474	55996	53263511
Contraindicated product administered	31.48	11.09	18	29541	135611	53183896
Exposure during pregnancy	31.30	11.09	15	29544	124845	53194662
Drug hypersensitivity	27.44	11.09	67	29492	265175	53054332
Hypomagnesaemia	27.05	11.09	49	29510	24762	53294745
Swelling	26.06	11.09	41	29518	191064	53128443
Miosis	25.47	11.09	25	29534	6977	53312530
Arrhythmia	25.20	11.09	60	29499	36719	53282788
Tongue oedema	25.08	11.09	20	29539	4247	53315260
Asthenia	24.77	11.09	295	29264	343295	52976212
Hypertension	24.66	11.09	211	29348	225220	53094287
Disorientation	24.62	11.09	62	29497	39297	53280210
Erythrosis	24.29	11.09	6	29553	64	53319443
Primary hyperaldosteronism	24.12	11.09	6	29553	66	53319441
Infusion related reaction	23.68	11.09	31	29528	155926	53163581
Cholestasis	23.21	11.09	50	29509	28645	53290862
Arthralgia	23.05	11.09	146	29413	439637	52879870
Chronic pigmented purpura	22.79	11.09	6	29553	84	53319423
Presyncope	22.76	11.09	47	29512	26147	53293360
Abdominal discomfort	22.73	11.09	56	29503	221006	53098501
Retroperitoneal haematoma	22.53	11.09	16	29543	2854	53316653
Sopor	22.17	11.09	41	29518	21043	53298464
Resting tremor	21.86	11.09	10	29549	769	53318738
International normalised ratio increased	21.73	11.09	67	29492	47694	53271813
Systemic infection	21.72	11.09	14	29545	2131	53317376
Infection	21.58	11.09	39	29520	172166	53147341
Walking disability	21.20	11.09	12	29547	1445	53318062
Renin decreased	21.03	11.09	6	29553	115	53319392
Rectal haemorrhage	20.58	11.09	60	29499	41421	53278086
Rash	20.00	11.09	155	29404	446036	52873471
Haematoma muscle	19.81	11.09	9	29550	681	53318826
Hypersensitivity pneumonitis	19.43	11.09	14	29545	2556	53316951
Sprue-like enteropathy	19.29	11.09	8	29551	485	53319022
Drop attacks	19.08	11.09	9	29550	742	53318765
Orthostatic hypotension	18.74	11.09	47	29512	29706	53289801
Oedema peripheral	18.74	11.09	160	29399	170627	53148880
Adenocarcinoma metastatic	18.67	11.09	5	29554	75	53319432
Arterial spasm	18.67	11.09	5	29554	75	53319432
Blood aldosterone increased	18.49	11.09	6	29553	180	53319327
Angioedema	18.20	11.09	58	29501	42018	53277489
Hemiparesis	18.03	11.09	38	29521	21437	53298070
Aeromonas infection	17.87	11.09	5	29554	89	53319418
Lactic acidosis	17.64	11.09	53	29506	37200	53282307
Cerebral haematoma	17.58	11.09	15	29544	3499	53316008
Face oedema	17.21	11.09	36	29523	20204	53299303
Peripheral ischaemia	17.14	11.09	17	29542	4802	53314705
Hypoosmolar state	17.09	11.09	6	29553	230	53319277
Urine output increased	17.07	11.09	10	29549	1284	53318223
Death	16.99	11.09	122	29437	357110	52962397
Haematoma	16.83	11.09	49	29510	33795	53285712
Cerebral salt-wasting syndrome	16.81	11.09	4	29555	36	53319471
Hypoglycaemia	16.78	11.09	71	29488	58942	53260565
Agranulocytosis	16.54	11.09	39	29520	23710	53295797
Drug intolerance	16.12	11.09	59	29500	205434	53114073
Microcytic anaemia	16.02	11.09	14	29545	3371	53316136
Product measured potency issue	15.94	11.09	5	29554	134	53319373
Sinus arrhythmia	15.55	11.09	10	29549	1517	53317990
Nocturia	15.27	11.09	20	29539	7630	53311877
Dry gangrene	15.14	11.09	7	29552	552	53318955
Blood pressure increased	15.08	11.09	131	29428	140348	53179159
Platelet disorder	14.94	11.09	10	29549	1621	53317886
Diffuse large B-cell lymphoma stage II	14.94	11.09	4	29555	60	53319447
Peripheral artery stenosis	14.69	11.09	7	29552	591	53318916
Nasopharyngitis	14.57	11.09	56	29503	192239	53127268
Blood loss anaemia	14.50	11.09	21	29538	8802	53310705
Nasal mucosal erosion	14.47	11.09	4	29555	68	53319439
Erysipelas	14.44	11.09	19	29540	7282	53312225
Product use issue	13.84	11.09	36	29523	139548	53179959
Elephantiasis	13.82	11.09	3	29556	17	53319490
Metabolic acidosis	13.74	11.09	53	29506	42189	53277318
Thrombocytopenia	13.68	11.09	127	29432	138600	53180907
Sinus bradycardia	13.64	11.09	27	29532	14574	53304933
Drug abuse	13.63	11.09	72	29487	65454	53254053
Vascular encephalopathy	13.27	11.09	6	29553	449	53319058
Electrolyte imbalance	13.14	11.09	31	29528	18853	53300654
Atrioventricular block complete	13.06	11.09	19	29540	7996	53311511
Intraventricular haemorrhage	13.03	11.09	10	29549	2008	53317499
Renal failure	13.00	11.09	111	29448	118341	53201166
Pericarditis	12.98	11.09	10	29549	64396	53255111
Anuria	12.84	11.09	24	29535	12416	53307091
Disease progression	12.83	11.09	23	29536	101897	53217610
Hyperammonaemia	12.75	11.09	15	29544	5134	53314373
Diarrhoea	12.72	11.09	444	29115	625102	52694405
Loss of personal independence in daily activities	12.65	11.09	12	29547	69803	53249704
Diaphragmatic disorder	12.40	11.09	6	29553	524	53318983
Intra-abdominal haematoma	12.33	11.09	9	29550	1676	53317831
Ductal adenocarcinoma of pancreas	12.23	11.09	4	29555	123	53319384
Inappropriate antidiuretic hormone secretion	12.03	11.09	26	29533	14925	53304582
Affective disorder	11.87	11.09	15	29544	5524	53313983
Prescription drug used without a prescription	11.82	11.09	9	29550	1785	53317722
Hypovolaemic shock	11.75	11.09	15	29544	5582	53313925
Dysarthria	11.68	11.09	49	29510	40519	53278988
Impaired healing	11.67	11.09	11	29548	64194	53255313
Discomfort	11.61	11.09	22	29537	95450	53224057
Action tremor	11.61	11.09	5	29554	333	53319174
Withdrawal hypertension	11.58	11.09	4	29555	146	53319361
Sinusitis	11.57	11.09	51	29508	168513	53150994
Jaundice	11.52	11.09	40	29519	30273	53289234
Hypersensitivity	11.49	11.09	69	29490	210596	53108911
Haemorrhagic stroke	11.41	11.09	15	29544	5743	53313764
Bacterial pyelonephritis	11.38	11.09	5	29554	350	53319157
Musculoskeletal stiffness	11.35	11.09	33	29526	123335	53196172
Epistaxis	11.34	11.09	71	29488	68639	53250868
Pancreatitis acute	11.30	11.09	36	29523	26073	53293434
Psychotic behaviour	11.27	11.09	6	29553	641	53318866
Shock haemorrhagic	11.13	11.09	19	29540	9164	53310343

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	129.76	11.50	496	23795	292972	32196263
Hyperkalaemia	117.52	11.50	197	24094	69553	32419682
Bradycardia	91.09	11.50	179	24112	71383	32417852
Lactic acidosis	77.94	11.50	110	24181	33426	32455809
Hypokalaemia	46.51	11.50	117	24174	54977	32434258
Hypoparathyroidism	44.78	11.50	16	24275	475	32488760
Death	43.50	11.50	144	24147	382373	32106862
Toxicity to various agents	39.40	11.50	45	24246	177996	32311239
Syncope	37.62	11.50	150	24141	89974	32399261
Hypotension	37.02	11.50	282	24009	215828	32273407
Hypertensive crisis	35.20	11.50	38	24253	8779	32480456
Renal artery thrombosis	35.05	11.50	12	24279	313	32488922
Cerebral haematoma	33.09	11.50	28	24263	4783	32484452
Cardiac failure	30.88	11.50	143	24148	91530	32397705
Burnout syndrome	30.71	11.50	9	24282	139	32489096
Presyncope	30.59	11.50	50	24241	17251	32471984
Shock haemorrhagic	29.41	11.50	38	24253	10607	32478628
Product monitoring error	28.77	11.50	20	24271	2554	32486681
Cerebellar ischaemia	27.76	11.50	8	24283	116	32489119
Labelled drug-drug interaction medication error	27.76	11.50	40	24251	12373	32476862
Coma	27.47	11.50	82	24209	42530	32446705
Ischaemic stroke	27.38	11.50	48	24243	17528	32471707
Cerebellar syndrome	26.99	11.50	18	24273	2148	32487087
Melaena	26.54	11.50	71	24220	34594	32454641
Pemphigoid	26.31	11.50	32	24259	8404	32480831
Febrile neutropenia	25.59	11.50	31	24260	119535	32369700
Blood lactic acid	25.45	11.50	10	24281	388	32488847
Vertigo	25.29	11.50	56	24235	24227	32465008
Renal failure	24.98	11.50	179	24112	134299	32354936
White blood cell count decreased	24.92	11.50	19	24272	91179	32398056
Coma uraemic	23.63	11.50	6	24285	52	32489183
Vascular purpura	23.62	11.50	15	24276	1647	32487588
Vitamin B12 decreased	23.55	11.50	13	24278	1103	32488132
Cardiac failure chronic	23.46	11.50	28	24263	7212	32482023
Cholestasis	23.41	11.50	58	24233	26975	32462260
Intercapillary glomerulosclerosis	23.33	11.50	6	24285	55	32489180
Brief psychotic disorder with marked stressors	23.25	11.50	8	24283	212	32489023
Hypertension	23.11	11.50	173	24118	131577	32357658
Angina pectoris	22.70	11.50	63	24228	31363	32457872
Cutaneous lupus erythematosus	22.58	11.50	11	24280	720	32488515
Renal impairment neonatal	22.23	11.50	5	24286	24	32489211
Platelet count decreased	22.18	11.50	32	24259	114559	32374676
Angioimmunoblastic T-cell lymphoma	22.14	11.50	9	24282	382	32488853
Renal ischaemia	21.69	11.50	10	24281	578	32488657
Antibody test abnormal	21.53	11.50	7	24284	155	32489080
Laryngeal cancer metastatic	21.50	11.50	6	24285	77	32489158
Anaemia	21.35	11.50	258	24033	223366	32265869
Orthostatic hypotension	21.13	11.50	54	24237	25596	32463639
Hepatic function abnormal	21.02	11.50	4	24287	44836	32444399
Drug interaction	20.95	11.50	252	24039	217933	32271302
Decreased ventricular preload	20.39	11.50	5	24286	37	32489198
Hepatocellular injury	19.52	11.50	52	24239	25266	32463969
Extrasystoles	19.39	11.50	19	24272	3918	32485317
Enzyme induction	19.33	11.50	5	24286	47	32489188
Bronchitis bacterial	19.10	11.50	10	24281	763	32488472
Agoraphobia	18.01	11.50	7	24284	264	32488971
Left ventricle outflow tract obstruction	17.80	11.50	6	24285	149	32489086
Carbohydrate metabolism disorder	17.65	11.50	4	24287	20	32489215
Infective exacerbation of chronic obstructive airways disease	17.52	11.50	13	24278	1838	32487397
Neurosis	17.44	11.50	6	24285	159	32489076
Potentiating drug interaction	17.27	11.50	20	24271	4988	32484247
Haematoma	17.09	11.50	50	24241	25634	32463601
Hypertensive nephropathy	17.03	11.50	8	24283	483	32488752
Transient ischaemic attack	16.96	11.50	50	24241	25744	32463491
Oral lichen planus	16.80	11.50	6	24285	178	32489057
Interstitial lung disease	16.69	11.50	94	24197	64907	32424328
Retinal disorder	16.59	11.50	10	24281	1001	32488234
Bundle branch block left	16.54	11.50	21	24270	5758	32483477
Electrocardiogram QT prolonged	16.53	11.50	66	24225	39575	32449660
Pain	16.51	11.50	78	24213	187478	32301757
Anticoagulation drug level increased	16.46	11.50	8	24283	521	32488714
Cranial sutures widening	16.45	11.50	5	24286	88	32489147
Dialysis device insertion	16.38	11.50	4	24287	29	32489206
Tooth avulsion	16.38	11.50	4	24287	29	32489206
Diabetic nephropathy	15.75	11.50	13	24278	2146	32487089
Metabolic alkalosis	15.56	11.50	11	24280	1443	32487792
Neutrophil count decreased	15.38	11.50	8	24283	47131	32442104
Electrocardiogram T wave abnormal	15.37	11.50	11	24280	1471	32487764
Perioral dermatitis	15.36	11.50	5	24286	111	32489124
Albumin urine present	15.19	11.50	7	24284	404	32488831
Blood creatine phosphokinase MB increased	14.62	11.50	12	24279	1965	32487270
Congenital inguinal hernia	14.58	11.50	5	24286	131	32489104
Haemorrhagic erosive gastritis	14.55	11.50	5	24286	132	32489103
Brain natriuretic peptide increased	14.54	11.50	17	24274	4283	32484952
Traumatic haemothorax	14.49	11.50	6	24285	267	32488968
Blood loss anaemia	14.06	11.50	23	24268	7939	32481296
Neonatal anuria	13.69	11.50	4	24287	61	32489174
Sinus bradycardia	13.65	11.50	30	24261	12908	32476327
Atrial tachycardia	13.61	11.50	12	24279	2165	32487070
Funguria	13.52	11.50	4	24287	64	32489171
Haemoglobinaemia	13.24	11.50	5	24286	174	32489061
Acute coronary syndrome	13.24	11.50	31	24260	13910	32475325
Cardioactive drug level decreased	13.24	11.50	4	24287	69	32489166
Carcinogenicity	13.18	11.50	4	24287	70	32489165
Glomerulonephritis membranous	13.07	11.50	9	24282	1132	32488103
Oligohydramnios	13.06	11.50	6	24285	344	32488891
Gingival discomfort	12.78	11.50	4	24287	78	32489157
Persistent foetal circulation	12.77	11.50	6	24285	362	32488873
Palpitations	12.75	11.50	57	24234	35912	32453323
Weight decreased	12.71	11.50	183	24108	164635	32324600
Conjunctival haemorrhage	12.63	11.50	13	24278	2842	32486393
Sepsis	12.31	11.50	69	24222	158765	32330470
Arterial stenosis	12.23	11.50	9	24282	1256	32487979
Creatinine urine increased	12.05	11.50	5	24286	224	32489011
IIIrd nerve disorder	11.92	11.50	4	24287	98	32489137
Acute pulmonary oedema	11.87	11.50	21	24270	7720	32481515
Pancreatitis acute	11.79	11.50	46	24245	27289	32461946
Normocytic anaemia	11.79	11.50	11	24280	2136	32487099
Eczema	11.78	11.50	31	24260	14949	32474286
Bone marrow failure	11.78	11.50	4	24287	30400	32458835

Pharmacologic Action:

Source	Code	Description
ATC	C07AB12	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Beta blocking agents, selective
ATC	C07BB12	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND THIAZIDES Beta blocking agents, selective, and thiazides
ATC	C07FB12	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS, OTHER COMBINATIONS Beta blocking agents and calcium channel blockers
ATC	C09DX05	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs), other combinations
FDA MoA	N0000000161	Adrenergic beta-Antagonists
FDA EPC	N0000175556	beta-Adrenergic Blocker
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists
MeSH PA	D058665	Adrenergic beta-1 Receptor Agonists
MeSH PA	D000318	Adrenergic beta-Agonists
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014665	Vasodilator Agents
CHEBI has role	CHEBI:35530	beta-adrenoceptor antagonists
CHEBI has role	CHEBI:35620	vasodilator
CHEBI has role	CHEBI:35674	antihypertensive
CHEBI has role	CHEBI:176497	anti-aging drugs

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Chronic heart failure	off-label use	48447003
Atrial fibrillation	off-label use	49436004	DOID:0060224
Angina pectoris	off-label use	194828000
Myocardial Reinfarction Prevention	off-label use
Bronchospasm	contraindication	4386001
Complete atrioventricular block	contraindication	27885002
Sick sinus syndrome	contraindication	36083008	DOID:13884
Bradycardia	contraindication	48867003
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Diabetes mellitus	contraindication	73211009	DOID:9351
Cardiogenic shock	contraindication	89138009
Second degree atrioventricular block	contraindication	195042002
Decompensated cardiac failure	contraindication	195111005
Disease of liver	contraindication	235856003	DOID:409
Hypoglycemic disorder	contraindication	237630007
Peripheral vascular disease	contraindication	400047006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.87	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 5MG BASE;80MG	BYVALSON	ALLERGAN	N206302	June 3, 2016	DISCN	TABLET	ORAL	7838552	Oct. 4, 2027	METHOD OF TREATING HYPERTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	ANTAGONIST	Ki	8.50	WOMBAT-PK	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	ANTAGONIST	Ki	7.50	WOMBAT-PK	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	8	WOMBAT-PK
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN	ANTAGONIST	Ki	5.66	IUPHAR

External reference:

ID	Source
4027169	VUID
N0000179202	NUI
D05127	KEGG_DRUG
152520-56-4	SECONDARY_CAS_RN
4027169	VANDF
C0068475	UMLSCUI
CHEBI:64022	CHEBI
CHEMBL434394	ChEMBL_ID
CHEMBL1201731	ChEMBL_ID
D000068577	MESH_DESCRIPTOR_UI
DB04861	DRUGBANK_ID
71301	PUBCHEM_CID
7246	IUPHAR_LIGAND_ID
5969	INN_ID
030Y90569U	UNII
236883	RXNORM
130026	MMSL
18486	MMSL
29969	MMSL
52690	MMSL
d05265	MMSL
007077	NDDF
007078	NDDF
318638009	SNOMEDCT_US
395808005	SNOMEDCT_US
734565001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1402	TABLET	2.50 mg	ORAL	NDA	26 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1405	TABLET	5 mg	ORAL	NDA	26 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1410	TABLET	10 mg	ORAL	NDA	26 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1420	TABLET	20 mg	ORAL	NDA	26 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7189	TABLET	5 mg	ORAL	ANDA	24 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7190	TABLET	10 mg	ORAL	ANDA	24 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7225	TABLET	2.50 mg	ORAL	ANDA	24 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7226	TABLET	20 mg	ORAL	ANDA	24 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	13668-353	TABLET	2.50 mg	ORAL	ANDA	23 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	13668-354	TABLET	5 mg	ORAL	ANDA	23 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	13668-355	TABLET	10 mg	ORAL	ANDA	23 sections
nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	13668-356	TABLET	20 mg	ORAL	ANDA	23 sections
Nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	31722-585	TABLET	2.50 mg	ORAL	ANDA	24 sections
Nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	31722-586	TABLET	5 mg	ORAL	ANDA	24 sections
Nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	31722-587	TABLET	10 mg	ORAL	ANDA	24 sections
Nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	31722-588	TABLET	20 mg	ORAL	ANDA	24 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1127	TABLET	5 mg	ORAL	NDA	26 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1307	TABLET	10 mg	ORAL	NDA	26 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3326	TABLET	20 mg	ORAL	NDA	26 sections
Nebivolol	Human Prescription Drug Label	1	50090-5708	TABLET	2.50 mg	ORAL	ANDA	24 sections
Nebivolol	Human Prescription Drug Label	1	50090-5752	TABLET	5 mg	ORAL	ANDA	24 sections
Nebivolol	Human Prescription Drug Label	1	50090-5761	TABLET	10 mg	ORAL	ANDA	24 sections
Nebivolol	Human Prescription Drug Label	1	50090-5775	TABLET	20 mg	ORAL	ANDA	24 sections
Nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	51407-483	TABLET	2.50 mg	ORAL	ANDA	25 sections
Nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	51407-484	TABLET	5 mg	ORAL	ANDA	25 sections
Nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	51407-485	TABLET	10 mg	ORAL	ANDA	25 sections
Nebivolol	HUMAN PRESCRIPTION DRUG LABEL	1	51407-486	TABLET	20 mg	ORAL	ANDA	25 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5944	TABLET	5 mg	ORAL	NDA	28 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6018	TABLET	10 mg	ORAL	NDA	28 sections
Bystolic	HUMAN PRESCRIPTION DRUG LABEL	1	55154-4621	TABLET	5 mg	ORAL	NDA	25 sections